Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cardiovasc Diabetol
Auteurs principaux: Husain, Mansoor, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://ncbi.nlm.nih.gov/pubmed/32998732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01106-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires